Zeo ScientifiX, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZEOX research report →
Price Chart
About the company
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company specializing in developing biological therapeutics aimed at treating degenerative diseases and fostering regenerative medicine. Its flagship investigational product, Zofin, is an acellular biologic therapy sourced from perinatal materials.
- CEO
- Ian T. Bothwell
- IPO
- 2016
- Employees
- 20
- HQ
- Davie, FL, US
Get TickerSpark's AI analysis on ZEOX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.40M
- P/E
- -2.07
- PEG
- -0.03
- P/S
- 1.35
- P/B
- 13.07
- EV/EBITDA
- -2.05
- Div Yield
- 0.00%
- Gross Margin
- 81.52%
- Op Margin
- -59.10%
- Net Margin
- -55.59%
- ROE
- 455.87%
- ROIC
- -511.01%
Latest fiscal year · YoY change
- Revenue
- $5.20M+12.5%
- Gross Profit
- $4.27M+13.0%
- Op Income
- $-5,386,000
- Net Income
- $-5,521,000-17.3%
- EPS
- $-0.86-16.2%
- OCF Growth
- +50.5%
- FCF Growth
- +48.9%
- 52W High
- $2.99
- 52W Low
- $0.97
- 50D MA
- $1.34
- 200D MA
- $1.91
- Beta
- 1.74
- RSI (14)
- 43
- Avg Volume
- 4.52K
No earnings-call transcripts are available for ZEOX yet.
- Free Float
- 47.4%
- Shares Outstanding
- 7.84M
- Float Shares
- 3.71M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 10, 26 | Grey Wendy | other | 625,000 |
| Jun 10, 26 | BOTHWELL IAN T | other | 625,000 |
| Jun 10, 26 | Shapiro George Craig | other | 625,000 |
| Jun 10, 26 | Bretz Charles Luther | other | 80,000 |
| Jan 23, 26 | Kisiday John David | other | 0 |
| Jan 14, 26 | Grey Wendy | other | 175,000 |
| Jan 14, 26 | BOTHWELL IAN T | other | 175,000 |
| Jan 14, 26 | Shapiro George Craig | other | 175,000 |
| Jun 25, 25 | Skycrest Holdings, LLC | buy | 6,000 |
| Jun 20, 25 | Skycrest Holdings, LLC | buy | 1,002 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZEOX coverage
Recent articles, reports, and earnings notes.
No research on ZEOX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZEOX report →ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect
accessnewswire.com · Sep 15
ZEO ScientifiX Announces Multidisciplinary Expert Faculty Lineup for the ZEO Xperience
accessnewswire.com · Sep 1
ZEO ScientifiX Launches First-of-Its-Kind ZEO Xperience, a Three-Day Immersive Regenerative Medicine Experience for Healthcare Professionals
accessnewswire.com · Aug 4
ZEO ScientifiX Strengthens South Florida's Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation
accessnewswire.com · Jul 21
ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026
accessnewswire.com · Jul 8
ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution
accessnewswire.com · Jul 1
ZEO ScientifiX Expands Medical Advisory Board with Leaders in Regenerative and Longevity Medicine
accessnewswire.com · Jun 9
ZEO ScientifiX Launches Physician-Led Patient Masterclass Program Following Grassroots Demand in the Southeast
accessnewswire.com · May 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.